Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.41 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL26599770 | 1.00 | HRH4 (0.48) | HRH4PRKCQHRH3PRKCDMCHR1 | |
| SCHEMBL26669816 | 0.88 | PRKCQ (0.48) | PRKCQHRH3PRKCDGPBAR1PRKD1 | |
| Trifluoroacetic Acid SCHEMBL26600250 | 0.76 | HRH4 (0.45) | HRH4HRH3PIM1PIM3PIM2 | |
| Trifluoroacetic Acid SCHEMBL26600264 | 0.76 | HRH4 (0.45) | HRH4HRH3PIM1PIM3PIM2 | |
| Trifluoroacetic Acid SCHEMBL1026901 | 0.74 | FFAR4 (0.51) | HRH4HRH3 | |
| SCHEMBL27635882 | 0.73 | PRKCQ (0.47) | PRKCQHRH3PRKCDPRKD1PRKD2 | |
| SCHEMBL27635881 | 0.73 | PRKCQ (0.47) | PRKCQHRH3PRKCDPRKD1PRKD2 | |
| Trifluoroacetic Acid SCHEMBL26600759 | 0.73 | CYP2C19 (0.44) | HRH4PRKCQMCHR1 | |
| Trifluoroacetic Acid SCHEMBL26600766 | 0.73 | CYP2C19 (0.44) | HRH4PRKCQMCHR1 | |
| SCHEMBL14258793 | 0.73 | PRKCQ (0.52) | HRH4PRKCQHRH3PRKCDGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| WO-2023205801-A2 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | HRH4 4558/4885PRKCQ 715/4885HRH3 4494/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | HRH4 4558/4885PRKCQ 715/4885HRH3 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.